308 related articles for article (PubMed ID: 27262225)
1. Long-term Anticoagulation With Rivaroxaban for Preventing Recurrent VTE: A Benefit-Risk Analysis of EINSTEIN-Extension.
Wells PS; Prins MH; Levitan B; Beyer-Westendorf J; Brighton TA; Bounameaux H; Cohen AT; Davidson BL; Prandoni P; Raskob GE; Yuan Z; Katz EG; Gebel M; Lensing AWA
Chest; 2016 Nov; 150(5):1059-1068. PubMed ID: 27262225
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
Coleman CI; Bunz TJ; Turpie AGG
Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322
[TBL] [Abstract][Full Text] [Related]
3. Cost comparison of continued anticoagulation with rivaroxaban versus placebo based on the 1-year EINSTEIN-Extension trial efficacy and safety results.
Wells PS; Lensing AWA; Haskell L; Levitan B; Laliberté F; Durkin M; Ashton V; Xiao Y; Crivera C; Lejeune D; Schein J; Lefebvre P
J Med Econ; 2018 Jun; 21(6):587-594. PubMed ID: 29469638
[TBL] [Abstract][Full Text] [Related]
4. Risk for Venous Thromboembolism Recurrence Among Rivaroxaban-treated Patients Who Continued Versus Discontinued Therapy: Analyses Among Patients with VTE.
Khorana AA; Berger JS; Wells PS; Seheult R; Ashton V; Laliberté F; Crivera C; Lejeune D; Schein J; Wildgoose P; Lefebvre P; Kaatz S
Clin Ther; 2017 Jul; 39(7):1396-1408. PubMed ID: 28645879
[TBL] [Abstract][Full Text] [Related]
5. Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial. Rationale and Design of the CASSINI Trial.
Khorana AA; Vadhan-Raj S; Kuderer NM; Wun T; Liebman H; Soff G; Belani C; O'Reilly EM; McBane R; Eikelboom J; Damaraju CV; Beyers K; Dietrich F; Kakkar AK; Riess H; Peixoto RD; Lyman GH
Thromb Haemost; 2017 Nov; 117(11):2135-2145. PubMed ID: 28933799
[TBL] [Abstract][Full Text] [Related]
6. Oral rivaroxaban for symptomatic venous thromboembolism.
; Bauersachs R; Berkowitz SD; Brenner B; Buller HR; Decousus H; Gallus AS; Lensing AW; Misselwitz F; Prins MH; Raskob GE; Segers A; Verhamme P; Wells P; Agnelli G; Bounameaux H; Cohen A; Davidson BL; Piovella F; Schellong S
N Engl J Med; 2010 Dec; 363(26):2499-510. PubMed ID: 21128814
[TBL] [Abstract][Full Text] [Related]
7. Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism.
Weitz JI; Lensing AWA; Prins MH; Bauersachs R; Beyer-Westendorf J; Bounameaux H; Brighton TA; Cohen AT; Davidson BL; Decousus H; Freitas MCS; Holberg G; Kakkar AK; Haskell L; van Bellen B; Pap AF; Berkowitz SD; Verhamme P; Wells PS; Prandoni P;
N Engl J Med; 2017 Mar; 376(13):1211-1222. PubMed ID: 28316279
[TBL] [Abstract][Full Text] [Related]
8. Influence of statin use on the incidence of recurrent venous thromboembolism and major bleeding in patients receiving rivaroxaban or standard anticoagulant therapy.
Wells PS; Gebel M; Prins MH; Davidson BL; Lensing AW
Thromb J; 2014; 12():26. PubMed ID: 25698905
[TBL] [Abstract][Full Text] [Related]
9. Rivaroxaban: a review of its use in the treatment of deep vein thrombosis or pulmonary embolism and the prevention of recurrent venous thromboembolism.
Burness CB; Perry CM
Drugs; 2014 Feb; 74(2):243-62. PubMed ID: 24430916
[TBL] [Abstract][Full Text] [Related]
10. The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implications.
Raskob GE; Spyropoulos AC; Zrubek J; Ageno W; Albers G; Elliott CG; Halperin J; Haskell L; Hiatt WR; Maynard GA; Peters G; Spiro T; Steg PG; Suh EY; Weitz JI
Thromb Haemost; 2016 Jun; 115(6):1240-8. PubMed ID: 26842902
[TBL] [Abstract][Full Text] [Related]
11. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials.
Prins MH; Lensing AW; Brighton TA; Lyons RM; Rehm J; Trajanovic M; Davidson BL; Beyer-Westendorf J; Pap ÁF; Berkowitz SD; Cohen AT; Kovacs MJ; Wells PS; Prandoni P
Lancet Haematol; 2014 Oct; 1(1):e37-46. PubMed ID: 27030066
[TBL] [Abstract][Full Text] [Related]
12. Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin.
Prandoni P; Lensing AWA; Prins MH; Gebel M; Pap AF; Homering M; Bauersachs R; Beyer-Westendorf J; Bounameaux H; Cohen AT; Davidson BL; van Bellen B; Verhamme P; Wells PS; Yuan Z; Levitan B; Weitz JI
Thromb Res; 2018 Aug; 168():121-129. PubMed ID: 30064683
[TBL] [Abstract][Full Text] [Related]
13. Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism. Rationale for and design of the EINSTEIN CHOICE study.
Weitz JI; Bauersachs R; Beyer-Westendorf J; Bounameaux H; Brighton TA; Cohen AT; Davidson BL; Holberg G; Kakkar A; Lensing AW; Prins M; Haskell L; van Bellen B; Verhamme P; Wells PS; Prandoni P;
Thromb Haemost; 2015 Aug; 114(3):645-50. PubMed ID: 25994838
[TBL] [Abstract][Full Text] [Related]
14. Rivaroxaban for treatment of venous thromboembolism in older adults.
Mitchell AP; Conway SE
Consult Pharm; 2014 Sep; 29(9):627-30. PubMed ID: 25203412
[TBL] [Abstract][Full Text] [Related]
15. Rivaroxaban for the treatment of venous thromboembolism. The SWIss Venous ThromboEmbolism Registry (SWIVTER).
Kucher N; Aujesky D; Beer JH; Mazzolai L; Baldi T; Banyai M; Hayoz D; Kaeslin T; Korte W; Escher R; Husmann M; Frauchiger B; Baumgartner I; Spirk D
Thromb Haemost; 2016 Aug; 116(3):472-9. PubMed ID: 27346301
[TBL] [Abstract][Full Text] [Related]
16. Rivaroxaban for the treatment of venous thromboembolism. A "real-life" perspective in 103 patients.
Jara-Palomares L; Sanchez-Oro-Gomez R; Elias-Hernandez T; Morillo-Guerrero R; Ferrer-Galvan M; Asensio-Cruz MI; Barrot-Cortes E; Otero-Candelera R
Thromb Res; 2014 Sep; 134(3):617-21. PubMed ID: 25034320
[TBL] [Abstract][Full Text] [Related]
17. Utility of a Nurse-Led Pathway for Patients with Acute Venous Thromboembolism Discharged on Rivaroxaban: A Prospective Cohort Study.
Lim MS; Indran T; Cummins A; Bennett A; Wood E; Brown S; McQuilten Z; Tran H; Epi MC; Chan NC; Chunilal S
Semin Thromb Hemost; 2019 Mar; 45(2):187-195. PubMed ID: 30566971
[TBL] [Abstract][Full Text] [Related]
18. Rivaroxaban versus standard anticoagulation for symptomatic venous thromboembolism (REMOTEV observational study): Analysis of 6-month outcomes.
Gaertner S; Cordeanu EM; Nouri S; Faller AM; Frantz AS; Mirea C; Bilbault P; Ohlmann P; Le Ray I; Stephan D
Int J Cardiol; 2017 Jan; 226():103-109. PubMed ID: 27806307
[TBL] [Abstract][Full Text] [Related]
19. Health-care Cost Impact of Continued Anticoagulation With Rivaroxaban vs Aspirin for Prevention of Recurrent Symptomatic VTE in the EINSTEIN-CHOICE Trial Population.
Wells PS; Prins MH; Beyer-Westendorf J; Lensing AWA; Haskell L; Levitan B; Laliberté F; Ashton V; Xiao Y; Lejeune D; Crivera C; Lefebvre P; Zhao Q; Yuan Z; Schein J; Prandoni P
Chest; 2018 Dec; 154(6):1371-1378. PubMed ID: 30201406
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of extended duration anticoagulation with rivaroxaban to prevent recurrent venous thromboembolism.
Coleman CI; Limone BL; Bookhart BK; Mody SH; Nutescu EA
Thromb Res; 2014 May; 133(5):743-9. PubMed ID: 24582461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]